NEW YORK, Sept. 13 (GenomeWeb News) - Blue Heron Biotechnology said last week that it has received a phase I small business innovative research grant from the National Institutes of Health to develop a universal restriction enzyme system.
The grant, worth $137,910, was awarded by the National Institute of General Medical Science and the National Human Genome Research Institute, said Blue Heron.
According to the company, the goal of the grant project is to develop "a uniform method for assembling large DNA molecules by ligation of sticky-ended fragments, regardless of the sequence, the fragment length, or the presence of restriction sites." This method, Blue Heron said, is expected to allow the use of restriction digestion to release any cloned fragment and allow complete control of the sticky ends on these fragments.